N-Deacetylthiocolchicine
N-Deacetylthiocolchicine is a tubulin inhibitor with an IC50 value of 2.2 nM in MDR-negative MDA-MB 231 breast cancer cells. N-Deacetylthiocolchicine exerts antiproliferative activity by binding to tubulin to interfere with microtubule assembly, arresting cells in mitosis during the cell cycle. N-Deacetylthiocolchicine is promising for research of malignancies such as breast cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 2731-16-0
- Formel: C20H23NO4S
- Molecular Weight:373.47
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | ED50 |
0.0077 μg/mL
Compound: 4
|
Cytotoxicity against human A549 cells after 2 days
Cytotoxicity against human A549 cells after 2 days
|
[PMID: 20542428] |
| A549 | IC50 |
11 nM
Compound: DTCOLCH
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
|
[PMID: 34592435] |
| A549 | IC50 |
24.1 nM
Compound: 3
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay
|
[PMID: 33465696] |
| BALB/3T3 | IC50 |
15.4 nM
Compound: DTCOLCH
|
Cytotoxicity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 34592435] |
| BALB/3T3 | IC50 |
223 nM
Compound: 3
|
Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay
|
[PMID: 33465696] |
| CA46 | IC50 |
38 μM
Compound: 6a
|
Inhibits the growth of the human Burkitt lymphoma CA46 cell
Inhibits the growth of the human Burkitt lymphoma CA46 cell
|
[PMID: 9083485] |
| DLD-1 | IC50 |
1180 nM
Compound: 7
|
Cytotoxicity against human DLD1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human DLD1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 30429975] |
| DU-145 | ED50 |
0.0018 μg/mL
Compound: 4
|
Cytotoxicity against human DU145 cells after 2 days
Cytotoxicity against human DU145 cells after 2 days
|
[PMID: 20542428] |
| H9 | EC50 |
0.013 μM
Compound: 10
|
Cytotoxicity against human H9 cells
Cytotoxicity against human H9 cells
|
[PMID: 1919593] |
| H9 | IC50 |
0.013 μM
Compound: 10
|
Antiviral activity against HIV1 HTLV-3B in human H9 cells after 3 days by p24 antigen capture assay
Antiviral activity against HIV1 HTLV-3B in human H9 cells after 3 days by p24 antigen capture assay
|
[PMID: 1919593] |
| HCT-8 | ED50 |
0.005 μg/mL
Compound: 4
|
Cytotoxicity against human HCT8 cells after 2 days
Cytotoxicity against human HCT8 cells after 2 days
|
[PMID: 20542428] |
| HeLa | GI50 |
0.014 μM
Compound: 11a
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell number incubated for 72 hrs
Antiproliferative activity against human HeLa cells assessed as reduction in cell number incubated for 72 hrs
|
[PMID: 30996805] |
| HepG2 | GI50 |
0.018 μM
Compound: 11a
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell number incubated for 72 hrs
Antiproliferative activity against human HepG2 cells assessed as reduction in cell number incubated for 72 hrs
|
[PMID: 30996805] |
| IGROV-1 | IC50 |
0.023 μM
Compound: 2
|
Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs by Coulter counting analysis
Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs by Coulter counting analysis
|
[PMID: 19833515] |
| KB | ED50 |
0.0018 μg/mL
Compound: 4
|
Cytotoxicity against human KB cells after 2 days
Cytotoxicity against human KB cells after 2 days
|
[PMID: 20542428] |
| L1210 | IC50 |
40 nM
Compound: 31
|
In vitro cytotoxicity against L1210 (murine leukemia) cells.
In vitro cytotoxicity against L1210 (murine leukemia) cells.
|
[PMID: 2299625] |
| LoVo | IC50 |
10.3 nM
Compound: DTCOLCH
|
Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
|
[PMID: 34592435] |
| LoVo | IC50 |
1020 nM
Compound: 7
|
Cytotoxicity against human LoVo cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human LoVo cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 30429975] |
| LoVo | IC50 |
16.9 nM
Compound: 3
|
Antiproliferative activity against human LoVo cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human LoVo cells incubated for 72 hrs by SRB assay
|
[PMID: 33465696] |
| MCF7 | GI50 |
0.018 μM
Compound: 11a
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell number incubated for 72 hrs
Antiproliferative activity against human MCF7 cells assessed as reduction in cell number incubated for 72 hrs
|
[PMID: 30996805] |
| MCF7 | IC50 |
14.2 nM
Compound: 3
|
Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by SRB assay
|
[PMID: 33465696] |
| MCF7 | IC50 |
4200 nM
Compound: 3
|
Anti tumor activity on human breast cancer cell line MDR-positive MCF-7 ADRr after 72 hours of treatment
Anti tumor activity on human breast cancer cell line MDR-positive MCF-7 ADRr after 72 hours of treatment
|
[PMID: 10602712] |
| MCF7 | IC50 |
670 nM
Compound: 7
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 30429975] |
| MCF7 | IC50 |
9.5 nM
Compound: DTCOLCH
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
|
[PMID: 34592435] |
| MDA-MB-231 | IC50 |
1260 nM
Compound: 7
|
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 30429975] |
| MDA-MB-231 | IC50 |
2.2 nM
Compound: 3
|
Anti tumor activity on human breast cancer cell line MDR-negative MDA-MB 231 after 72 hours of treatment
Anti tumor activity on human breast cancer cell line MDR-negative MDA-MB 231 after 72 hours of treatment
|
[PMID: 10602712] |
| SK-BR-3 | ED50 |
0.0016 μg/mL
Compound: 4
|
Cytotoxicity against human SKBR3 cells after 2 days
Cytotoxicity against human SKBR3 cells after 2 days
|
[PMID: 20542428] |
| SK-OV-3 | IC50 |
1.3 nM
Compound: 7
|
Cytotoxicity against human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 30429975] |
| SK-OV-3 | IC50 |
9.6 nM
Compound: 7
|
Cytotoxicity against arrested non-proliferative human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against arrested non-proliferative human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 30429975] |
Chemical Information
-
CAS. Nr. 2731-16-0
-
Molecular Weight 373.47
-
Formel C20H23NO4S
-
SMILES
COC1=C(C(C([C@@H](N)CC2)=C3)=CC=C(SC)C3=O)C2=CC(OC)=C1OC
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Reinheit & Dokumentation
Verweise
[1]. Gelmi ML, et al. N-deacetyl-N-aminoacylthiocolchicine derivatives: synthesis and biological evaluation on MDR-positive and MDR-negative human cancer cell lines. J Med Chem. 1999 Dec 16;42(25):5272-6. [Content Brief]
[2]. Barešić M, et al. Different Therapeutic Paths (Colchicine vs. Anakinra) in Two Patients With Schnitzler's Syndrome. Arch Rheumatol. 2016 Jul 11;31(4):377-380. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)